MedTrace Logo

Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

NCT00632255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2019-07-08

No results posted yet for this study

Summary

Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML). The first clinical trials were conducted in 1998 in patients with advanced disease, and by 2002 imatinib was established as the standard therapy for all patients including those recently diagnosed. In spite of overwhelming evidence about its efficacy we still need to gain more knowledge about issues related to long term treatment with imatinib such as why some patients respond better than others, the development of side effects and the quality of life.

Conditions

  • Chronic Myeloid Leukemia
  • Newly Diagnosed

Interventions

DRUG

Imatinib

Conventional therapy with imatinib

Sponsors & Collaborators

Principal Investigators

  • David Marin, Consultant Haematology · Imperial College Healthcare NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00632255 on ClinicalTrials.gov